1.Practice and Exploration of Clinical Pharmacy of Traditional Chinese and Western Integrative Medicine in a Special Hospital
Zhilei QIAN ; Lei LU ; Liang ZHANG ; Qiuyun ZHOU ; Hongzi DING ; Jie WANG
China Pharmacist 2015;(11):1901-1903
Objective: To summarize the experience of clinical pharmacy of traditional Chinese medicine in a special hospital. Methods: Combining the work of clinical pharmacists in the hospital, the service content of clinical pharmacy of traditional Chinese medicine in the special hospital was described and the improvement methods were explored. Results:The pharmaceutical care of clini-cal pharmacy of traditional Chinese medicine could improve safe and rational use of drugs. Conclusion: Pharmacists should enhance the study of pharmacy and traditional Chinese medicine to improve the pharmaceutical care of clinical pharmacy of traditional Chinese medicine.
2.Analysis on the Causes of Clinical Return of PIVAS Finished Infusions in Our Hospital and Discussion on Intervention Strategies
Yang YANG ; Jie WANG ; Hongzi DING ; Qiuyun ZHOU ; Feng ZHAO ; Xinglan LU
China Pharmacy 2017;28(34):4894-4896
OBJECTIVE:To provide reference for reducing the clinical return of finished infusions. METHODS:Interventions for clinical return of PIVAS finished infusions in our hospital were introduced,the return situation of finished infusions before(dur-ing 2013-2014)and after(during 2015-2016)intervention was compared,and intervention effects were evaluated. RESULTS:Our hospital intervened it by rationally selecting and using syringes,strengthening visible particle check of finished infusion before dis-tribution;optimizing the order of drug configuration,reasonably arranging the drug infusion sequence;strengthening the clean-up in work area before drug infusion,correctly using disinfectant;strictly implementing intravenous infusion associative operation, playing the role of pharmacists;cultivating good work habits,and strengthening teamwork,etc. Compared with before interven-tion,the return numbers of finished infusion were decreased by 41.2%,and reported loss amount reduced by 45.7%. The return caused by visibility particles,finished infusion oxidation discoloration after too long storage time,finished infusion leakage,contin-uous infusion of drugs compatibility,heterodyne error,improper drug configuration method in packaging to the ward,improper use of disinfectant before infusion decreased by 25.3%,46.9%,39.4%,77.8%,73.9%,75.0%,100%,respectively. CONCLU-SIONS:Intervening the return of finished infusion can reduce the return numbers and drug waste.
3.Therapeutic observation and pharmacoeconomic analysis of two first-line chemo-therapy regimens in advanced NSCLC
Wenyu ZHU ; Qi JIANG ; Liang ZHANG ; Juan WU ; Jie WANG ; Hongzi DING
Journal of Pharmaceutical Practice 2018;36(2):176-179
Objective To evaluate the cost-effectiveness of two chemotherapy regimens in NSCLC for the purpose of lower cost,higher quality medical care.Methods 56 patients with advanced NSCLC were divided into two groups from our hospital,group PP(pemtrexal+cisplatin,n=30)and group GP(gemcitabine+cisplatin,n=26),and analyzed by pharmaco-economic cost-effectiveness method,and retrospective analysis was also applied.Results Effective rates of two regimens were 46.67%,42.31%,no significant difference.But there was significant difference in the incidence rate of ADR between the two groups.The cost of chemotherapy regiments were 31 985.48 and 27 683.15 yuan.The average length of stay was 10.94 and 13·91 days.Compared to group GP,for each unit of efficacy,the cost in group PP were increased 986.77 yuan.Conclusion From the analysis of cost-effectiveness,group PP had higher chemotherapy costs,but better safety than group GP.